Advanced liver fibrosis by transient elastography, Fibrosis 4, and alanine aminotransferase/platelet ratio index among Asian hepatitis C with and without human immunodeficiency virus infection: Role of vitamin D levels

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 9, 2014, Pages 1706-1714

  Avihingsanon, Anchalee ^a,b   Jitmitraparp, Salyavit ^b   Tangkijvanich, Pisit ^b   Ramautarsing, Reshmie A ^a,c   Apornpong, Tanakorn ^a   Jirajariyavej, Supunee ^d   Putcharoen, Opass ^e   Treeprasertsuk, Sombat ^b   Akkarathamrongsin, Srunthron ^b   Poovorawan, Yong ^b   Matthews, Gail V ^f   Lange, Joep Ma ^a,c   Ruxrungtham, Kiat ^a,b  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^d Taksin Hospital   (Thailand)

^e CHULALONGKORN UNIVERSITY   (Thailand)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

APRI; Fib 4; Genotype 3; Genotype 6; Hepatitis C; HIV hepatitis C co infection; Liver fibrosis; Thailand; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALANINE AMINOTRANSFERASE; INTERLEUKIN 28B; RNA; 25-HYDROXYVITAMIN D; BIOLOGICAL MARKER; VITAMIN D;

ADULT; ARTICLE; ASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ELASTOGRAPHY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; THAILAND; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; COMPLICATION; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ADULT; ALANINE TRANSAMINASE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; COINFECTION; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; THAILAND; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84906499244     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12613     Document Type: Article

References (34)

1. Palella FJ Jr, Delaney KM, Moorman AC etal. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 1998; 338: 853-860.
2. Weber R, Sabin CA, Friis-Moller N etal. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch. Intern. Med. 2006; 166: 1632-1641.
3. Mocroft A, Brettle R, Kirk O etal. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16: 1663-1671.
4. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet 2011; 377: 1198-1209.
5. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22: 1979-1991.
6. Benhamou Y, Bochet M, Di Martino V etal. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-1058.
7. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J. Hepatol. 2001; 34: 730-739.
8. Puoti M, Bonacini M, Spinetti A etal. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J. Infect. Dis. 2001; 183: 134-137.
9. Hull MW, Rollet K, Moodie EE etal. Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients. AIDS 2012; 26: 1789-1794.
10. Salmon D, Bani-Sadr F, Loko MA etal. Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH. J. Hepatol. 2012; 56: 862-868.
11. Collazos J, Carton JA, Asensi V. Gender differences in liver fibrosis and hepatitis C virus-related parameters in patients coinfected with human immunodeficiency virus. Curr. HIV Res. 2011; 9: 339-345.
12. Barreiro P, Martin-Carbonero L, Nunez M etal. Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3. Clin. Infect. Dis. 2006; 42: 1032-1039.
13. Terrier B, Carrat F, Geri G etal. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J. Hepatol. 2011; 55: 756-761.
14. Petta S, Camma C, Scazzone C etal. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51: 1158-1167.
15. Mandorfer M, Reiberger T, Payer BA etal. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients. AIDS 2013; 27: 227-232.
16. Kirk GD, Astemborski J, Mehta SH etal. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin. Infect. Dis. 2009; 48: 963-972.
17. Akkarathamrongsin S, Praianantathavorn K, Hacharoen N etal. Geographic distribution of hepatitis C virus genotype 6 subtypes in Thailand. J. Med. Virol. 2010; 82: 257-262.
18. Ziol M, Handra-Luca A, Kettaneh A etal. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.
19. Wai CT, Greenson JK, Fontana RJ etal. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
20. Sterling RK, Lissen E, Clumeck N etal. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325.
21. Martin-Carbonero L, Benhamou Y, Puoti M etal. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin. Infect. Dis. 2004; 38: 128-133.
22. Mohsen AH, Easterbrook PJ, Taylor C etal. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003; 52: 1035-1040.
23. Mendes-Correa MC, Widman A, Brussi ML, Guastini CF, Gianini RJ. Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C in Brazil. AIDS Patient Care STDS 2008; 22: 701-707.
24. Garcia F, Roldan C, Hernandez-Quero J etal. Relationship between viral genotype and viral load in patients with chronic hepatitis C. Eur. J. Clin. Microbiol. Infect. Dis. 1996; 15: 884-887.
25. Yoo TW, Donfield S, Lail A, Lynn HS, Daar ES. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J. Infect. Dis. 2005; 191: 4-10.
26. Cholet F, Nousbaum JB, Richecoeur M etal. Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients. Gastroenterol. Clin. Biol. 2004; 28: 272-278.
27. Hissar SS, Kumar M, Tyagi P etal. Natural history of hepatic fibrosis progression in chronic hepatitis C virus infection in India. J. Gastroenterol. Hepatol. 2009; 24: 581-587.
28. Castera L, Vergniol J, Foucher J etal. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350.
29. Boursier J, Vergniol J, Sawadogo A etal. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int. 2009; 29: 1507-1515.
30. Holick MF. Vitamin D deficiency. N. Engl. J. Med. 2007; 357: 266-281.
31. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J. Gastroenterol. 2011; 17: 5184-5190.
32. Monto A, Kakar S, Dove LM, Bostrom A, Miller EL, Wright TL. Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients. Am. J. Gastroenterol. 2006; 101: 1509-1515.
33. Macias J, Mira JA, Lopez-Cortes LF etal. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antivir. Ther. 2006; 11: 839-846.
34. Suarez-Zarracina T, Valle-Garay E, Collazos J etal. Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients. J. Viral Hepat. 2012; 19: 685-693.